Fenfluramine, and later cannabidiol was added on compassionate basis as it does not have an FDA approval for use in patients less than 1 year of age and in Dravet syndrome associated with the SCN1B genotype–phenotype. The gene discussed is SCN1B; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.